Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio’s ability to develop, manufacture, market and finance new products, Chembio's ability to integrate and operate opTricon GmbH in accordance with Chembio's business strategy, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission. © 2019 Chembio. All Rights Reserved. Page 2 Safe Harbor Statement

99.8% Sensitivity(1)100% Specificity(1) Patented DPP® Technology Platform (1) Based on fingerstick whole blood samples: DPP® HIV 1/2 Assay Product FeaturesSimple: easy to useFast: results in ~15 minutesReliable: FDA approved, CLIA waivedProduct UniquenessEnhanced sensitivity and specificityAdvanced multiplexing capabilitiesQuantitative results - with DPP® Micro Reader © 2019 Chembio. All Rights Reserved. Page 4 DPP® Test Cartridge

DPP® technology is enhanced through use of an optical analyzer Provides data capture, storage, and connectivity (e.g., Bluetooth, cloud, direct)Enables quantitative measurement Drives down level of detection and improves analytical sensitivitySimplifies interpretation of results compared to visually-read testsReduces transcription errors when interpreting a multiplex test Next Generation Analyzer DPP® Micro Reader Patented Optical Analyzer TechnologyAcquired opTricon GmbH (Q4 2018) © 2019 Chembio. All Rights Reserved. Page 5

Lateral Flow Test Market: $5.5B(1)Expected to grow at 8.2% CAGR(1), reaching $8.2B(1) (2022) © 2019 Chembio. All Rights Reserved. Page 6 Infectious disease is the largest and fastest growing segment, estimated at $1.4 billion(2) annually and growing at ~10% CAGR(2)Chembio is currently focused on three areas within the infectious disease market:Sexually Transmitted Disease testsMosquito-borne Disease testsHepatitis testsGrowth drivers include: high prevalence of infectious diseases worldwide, increase in geriatric population, growing demand for rapid test results, and multiplexing advancements (1) MarketsandMarkets 2018. (2) Management estimates.

HIV has claimed more than 35 million lives to date, including 940,000 in 2017(1)Approximately 36.9 million people were living with HIV at the end of 2017; 1.8 million people became newly infected in 2017(1)Syphilis = Estimated 18 million prevalent cases and 5.6 million new infections annually(2)Dengue = 390 million cases and 3.9 billion people at risk(4); malaria = 216 million cases causing 446 thousand deaths(3)Emerging markets: Zika, Chikungunya, Ebola, Lassa, Marburg, Leptospirosis, Burkholderia, Rickettsia Lateral Flow Infectious Disease MarketFocus on sexually transmitted and fever/tropical diseases HIV: 36.9M Syphilis: 18.0M (1) who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections. (2) WHO guidelines for the treatment of syphilis 2016. © 2019 Chembio. All Rights Reserved. Page 7 Global Prevalence Dengue: 390M Malaria: 214M Annual Cases (3) who.int/news-room/fact-sheets/detail/malaria. (4) who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

Increase market penetration in existing marketsUnited StatesBrazilAfricaEurope Register existing and new products into unchartered countries/regionsLatin AmericaSoutheast Asia Multiple Growth Drivers © 2019 Chembio. All Rights Reserved. Page 10 Expand commercial presenceEuropeUnited States

Expanding Product Approvals Geographically Product Name U.S. Int’l(1) DPP® HIV 1/2   DPP® HIV-Syphilis Pending FDA Approval  DPP® Syphilis Screen & Confirm  DPP® Dengue-Zika-Chikungunya  DPP® Dengue  DPP® Zika  FDA EUA  DPP® Chikungunya  DPP® Leishmania  STAT-PAK® HIV 1/2   SURE CHECK® HIV 1/2   SURE CHECK® HIV Self Test  (1) International markets require specific country registrations © 2019 Chembio. All Rights Reserved. Page 12

HIV-Syphilis Presents U.S. Growth OpportunityCo-infection and mother-to-child transmission are global health concerns Key AccomplishmentsDeveloped DPP® HIV-Syphilis multiplex testReceived regulatory approvals from ANVISA (Brazil), COFEPRIS (Mexico), CE mark (EU) Completed DPP® HIV-Syphilis U.S. clinical trialFiled FDA Pre-Market Approval (PMA) Application “In 2013, the World Health Organization (WHO) reported that 1.9 million pregnant women were infected with syphilis worldwide, of which 66.5% had adverse fetal effects in cases of untreated syphilis. Congenital syphilis contributes significantly to infant mortality, accounting for 305,000 perinatal deaths worldwide annually.”(1)“More than 1.4 million pregnant women are infected with HIV, and mother-to-child transmission (MTCT) of HIV is estimated to have resulted in over 150,000 infant cases in 2015.”(2) Next StepsAfter receipt of FDA approval, launch to U.S. moderately complex sites, and submit CLIA waiver applicationAfter receipt of CLIA Waiver, launch to U.S. CLIA Waived sitesContinue to pursue international registrations © 2019 Chembio. All Rights Reserved. Page 13 (1) ncbi.nlm.nih.gov/pmc/articles/PMC5738763. (2) ncbi.nlm.nih.gov/pmc/articles/PMC5486952/.

Chembio's Infectious Disease PipelinePresents multiple growth opportunities Product Name Collaborator Phase I(Feasibility) Phase II(Development) Phase III(Verification/Validation) Phase IV(Clinical/Regulatory) Phase V(Commercial Launch) DPP® HIV-Syphilis (US) Submitted FDA PMA Q1 2018 DPP® Dengue (Int’l) Received: ANVISA DPP® Dengue NS1 (Int’l) Ongoing DPP® Zika (US/Int’l) Received: FDA EUA, ANVISA, CE mark DPP® Chikungunya (Int’l) Received: ANVISA, Malaysia DPP® Dengue-Zika-Chikungunya (Int’l) Received: ANVISA, Malaysia DPP® Malaria (Int’l) Ongoing DPP® Ebola (US, Int’l) Ongoing Received: FDA EUA DPP® Fever Panel (Africa) Field Testing: Africa, South America DPP® Fever Panel (Asia) Ongoing © 2019 Chembio. All Rights Reserved. Page 15 Self-funded

Leverage our DPP® Technology PlatformWhat opportunities do our technology collaborations provide? Expansion into new marketsCancer DiagnosticsConcussion / Traumatic Brain InjuryVeterinaryBroadening application from POC diagnostics to companion diagnosticsDrugsVaccinesCost-effective research & development, fully funded by collaborators © 2019 Chembio. All Rights Reserved. Page 16

Chembio’s Technology CollaborationsProvides expansion into new markets and fully-funded R&D costs Product Name Collaborator Phase I(Feasibility) Phase II(Development) Phase III(Verification/Validation) Phase IV(Clinical/Regulatory) Phase V(Commercial Launch) DPP® Eosinophilic / Respiratory Ongoing Received CE mark DPP® Concussion Perseus Science Ongoing Infectious Disease Portfolio Ongoing DPP® Cancer Undisclosed DPP® Hepatitis C © 2019 Chembio. All Rights Reserved. Page 17

Deep scientific expertise with a proven technology platformSensitive and specificAdvanced multiplexing capabilitiesQuantitative resultsSuccessful track record developing DPP® tests with diverse collaboratorsGlobal commercial companiesGovernmentsNon-governmental organizationsExtensive experience achieving global regulatory approvalsU.S. FDA, WHO PQ, CE mark, ANVISA, COFEPRIS Why Global Leaders Choose Chembio © 2019 Chembio. All Rights Reserved. Page 18

Automate U.S. ManufacturingAutomated DPP® line commenced production Q1 2019 EfficientReduces variable costs to produce DPP® testsIntelligentEnhances inspection and quality control via vision-guided, robotic operationFlexibleAllows assembly of various configurations of DPP® tests on a single lineScalableExpands capacity by 5-10 million tests with each new line Chembio’s fully-automated DPP® assembly & packaging line © 2019 Chembio. All Rights Reserved. Page 20

Expand and Improve U.S. FacilitiesNew U.S. Headquarters: 555 Wireless Boulevard, Hauppauge, NY © 2019 Chembio. All Rights Reserved. Page 21 Facility consolidation, expansion and improvement occurs in three phasesPhase 1: Sales, Marketing, Finance, Regulatory, Warehouse, Distribution (H1 2019)Phase 2: Research & Development (H2 2019)Phase 3: Manufacturing, Quality Assurance, Quality Control (H1 2020)

Q1 2019 Financials Q1 2019 Q1 2018 RevenueGross marginOperating expenseCash balanceNet working capital $8.3 million42.5%$6.6 million(1)$7.4 million$19.9 million $7.7 million46.6%$4.3 million$12.5 million$18.5 million © 2019 Chembio. All Rights Reserved. Page 22 (1) Includes $0.4 million acquisition costs in Q1 2019

Five-year targets: 2023FY Revenue $100M and 2023YE 50% Gross Margins Proprietary DPP® technology platform with broad diagnostic applications, providing enhanced sensitivity and specificity, advanced multiplexing capabilities, and quantitative results Growing infectious disease business (39%) with ongoing initiatives to broaden sales channels, further penetrate existing markets, and expand into new territories(1) Broad R&D pipeline in infectious disease and expansion into new markets via collaborations (e.g., concussion, companion diagnostics, biothreat, veterinary, cancer)Operational initiatives underway to automate U.S. manufacturing and expand U.S. facilities to add capacity, reduce variable costs and drive margin expansion Investment Highlights (1) Based on total revenue 2018 vs. 2017 © 2019 Chembio. All Rights Reserved. Page 23